Chemotherapy

Neoadjuvant Chemotherapy May Confer Benefit in Pancreatic Adenocarcinoma

Neoadjuvant Chemotherapy May Confer Benefit in Pancreatic Adenocarcinoma

By

The addition of preoperative chemotherapy may eradicate micrometastatic disease and direct postoperative therapy in the case of resistance.

Uterine Re-Curettage May Not Affect Required Chemotherapy Courses in GTN

Uterine Re-Curettage May Not Affect Required Chemotherapy Courses in GTN

By

After the initial year of follow-up, 2 patients in the standard arm and 1 patient in the re-curettage arm had relapsed.

Mapping Chemotherapy Checking Procedures May Improve Safety

Mapping Chemotherapy Checking Procedures May Improve Safety

By

While checks were documented thoroughly in 3 centers, there were no internal standards for physician checks.

Metronomic Chemotherapy May Improve Outcomes Among Elderly Patients With HER2-Positive Breast Cancer

Metronomic Chemotherapy May Improve Outcomes Among Elderly Patients With HER2-Positive Breast Cancer

By

Researchers evaluated whether dual HER2 inhibition with trastuzumab and pertuzumab plus metronomic cyclophosphamide is superior to dual HER2 inhibition alone.

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2+ Breast Cancer

FDA Grants Breakthrough Therapy Designation to DS-8201 for HER2+ Breast Cancer

By

DS-8201 is an investigational HER2-targeting ADC, a targeted therapy for cancer that delivers cytotoxic chemotherapy by means of a linker on the monoclonal antibody that attaches to a specific target on cancer cells.

BRCA 1/2 Status in Triple-negative Breast Cancer May Affect Responsiveness to Carboplatin

BRCA 1/2 Status in Triple-negative Breast Cancer May Affect Responsiveness to Carboplatin

By

Patients with triple-negative breast cancer without BRCA1 and BRCA2 germline mutations may benefit from the addition of carboplatin to a chemotherapy regimen.

Evofosfamide Not Recommended in First-line Sarcoma Treatment

Evofosfamide Not Recommended in First-line Sarcoma Treatment

By

Adding evofosfamide to doxorubicin is not recommended as a first-line treatment for patients with advanced soft-tissue sarcoma.

Once-daily Radiotherapy Not Superior to Twice-daily in SCLC

Once-daily Radiotherapy Not Superior to Twice-daily in SCLC

By

Once-daily radiotherapy is not superior to twice-daily treatment for patients with small-cell lung cancer receiving concurrent chemoradiotherapy.

HPV, p16 Status May Affect Prognosis in HNSCC

HPV, p16 Status May Affect Prognosis in HNSCC

By

Among patients suffering post-radiation or chemoradiation locoregional HNSCC recurrence, those with HPV-positive disease may have better survival rates.

Histotype-guided Treatment Fails To Improve Outcomes in Sarcoma

Histotype-guided Treatment Fails To Improve Outcomes in Sarcoma

By

A standard chemotherapy regimen was more efficacious than histotype-guided chemotherapy among patients with high-risk, localized sarcoma of the extremities or trunk wall.

Chemotherapy- and Radiation-Induced Nausea and Vomiting:  An Overview

Chemotherapy- and Radiation-Induced Nausea and Vomiting: An Overview

By

A review of treatment options for patients experiencing chemotherapy- cr radiation-induced nausea and vomiting.

Chemotherapy-Induced and Radiotherapy-Induced Oral Mucositis

Chemotherapy-Induced and Radiotherapy-Induced Oral Mucositis

By

Many patients who receive chemotherapy or radiotherapy as a part of their treatment for cancer develop oral mucositis, which is a painful, debilitating condition.

Clinician Communication, Perceived Burden Critical for Adherence to Oral Chemotherapy

Clinician Communication, Perceived Burden Critical for Adherence to Oral Chemotherapy

By

Patients who reported better clinician communication or an improved satisfaction with their treatment were more likely to be adherent.

No Difference in Aprepitant vs Fosaprepitant in CINV

No Difference in Aprepitant vs Fosaprepitant in CINV

By

This study indicates that there is no difference in efficacy or safety between aprepitant and fosaprepitant, though the study was limited by its small sample size.

Docetaxel-based Perioperative Therapy Recommended in Gastric Cancer

Docetaxel-based Perioperative Therapy Recommended in Gastric Cancer

By

Study authors conclude that FLOT should be an internationally standard option for patients with resectable gastric cancer.

Adding Ramucirumab Does Not Improve PFS in Gastrointestinal Adenocarcinoma

Adding Ramucirumab Does Not Improve PFS in Gastrointestinal Adenocarcinoma

By

Adding ramucirumab to mFOLFOX6 therapy in an intent-to-treat population of patients with GEJ does not improve PFS.

Antipsychotic Drug Olanzapine Prevents Nausea for Patients Receiving Chemotherapy

Antipsychotic Drug Olanzapine Prevents Nausea for Patients Receiving Chemotherapy

By

Dopamine antagonist olanzapine prevents nausea and the complete response rate among previously untreated patients receiving highly emetogenic chemotherapy.

TAS-102 Ineffective for Treatment of Small Cell Lung Cancer

TAS-102 Ineffective for Treatment of Small Cell Lung Cancer

By

TAS-102 improved survival, when contrasted with placebo, for patients with refractory colorectal cancer, though the drug showed no activity for the second-line treatment of patients with small cell lung cancer.

Neratinib May Be Efficacious for Treatment of HER2-Positive Breast Cancer

Neratinib May Be Efficacious for Treatment of HER2-Positive Breast Cancer

By

Neratinib demonstrated clinical efficacy for patients with HER2-positive, hormone-receptor-negative breast cancer, in a phase 2 study.

Males With Recurrent Breast Cancer at Greater Risk of Mortality Than Females

Males With Recurrent Breast Cancer at Greater Risk of Mortality Than Females

By

Males with breast cancer are less likely to survive than females after disease recurrence, which may be due to less aggressive treatment after relapse.

Myeloma: Carfilzomib Superior to Bortezomib Regardless of Number of Prior Treatments

Myeloma: Carfilzomib Superior to Bortezomib Regardless of Number of Prior Treatments

By

Carfilzomib is superior to bortezomib for progression-free survival, regardless of previous treatments or prior exposure to either bortezomib or lenalidomide, for patients with multiple myeloma.

New Drug Combination May Be Beneficial for Newly-diagnosed Myeloma Patients

New Drug Combination May Be Beneficial for Newly-diagnosed Myeloma Patients

By

The combination of ixazomib, cyclophosphamide, and dexamethasone induced high response rates with good tolerability in patients with newly-diagnosed multiple myeloma.

Adjuvant Chemo With S-1 Effective for Resected Pancreatic Cancer in Japanese Patients

Adjuvant Chemo With S-1 Effective for Resected Pancreatic Cancer in Japanese Patients

By

Adjuvant chemotherapy with S-1 may improve standard of care for Japanese patients with resected pancreatic cancer.

Adding Olaratumab to Doxorubicin Improves Survival in Soft-tissue Sarcoma

Adding Olaratumab to Doxorubicin Improves Survival in Soft-tissue Sarcoma

By

Addition of olaratumab to doxorubicin significantly improves PFS and OS in patients with advanced soft-tissue sarcoma.

Gemcitabine Plus Capecitabine More Effective for Treatment of Pancreatic Cancer Than Gemcitabine Alone

Gemcitabine Plus Capecitabine More Effective for Treatment of Pancreatic Cancer Than Gemcitabine Alone

By

Gemcitabine plus capecitabine improves survival for patients with pancreatic cancer

FOLFIRINOX May Have Longer Median OS Than Gemcitabine for Pancreatic Cancer

FOLFIRINOX May Have Longer Median OS Than Gemcitabine for Pancreatic Cancer

By

First-line FOLFIRINOX treatment appears to result in a higher overall survival in patients with advanced pancreatic cancer.

EBCC-10: Studies Highlight Treatment Nuances on Breast Cancer Recurrence, Overall Survival

EBCC-10: Studies Highlight Treatment Nuances on Breast Cancer Recurrence, Overall Survival

By

Identifying HER2-pathway cancer "addicts," omitting adjuvant chemotherapy based on a 21-gene Recurrence Score, and improving survival with dose-dense chemotherapy were among the treatment topics highlighted.

NSCLC: Adding Ramucirumab to Docetaxel Does Not Impair Quality of Life

NSCLC: Adding Ramucirumab to Docetaxel Does Not Impair Quality of Life

By

The addition of ramucirumab to docetaxel improved clinical efficacy outcomes, without decreasing quality of life in non-small cell lung cancer.

Adding Ramucirumab to Paclitaxel Maintains QoL in Advanced Gastric Cancer

Adding Ramucirumab to Paclitaxel Maintains QoL in Advanced Gastric Cancer

By

The addition of ramucirumab to paclitaxel for treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma increased overall survival.

Nanoliposomal Irinotecan + Fluorouracil and Folinic Acid Extends Overall Survival in Patients with Metastatic Pancreatic Cancer

Nanoliposomal Irinotecan + Fluorouracil and Folinic Acid Extends Overall Survival in Patients with Metastatic Pancreatic Cancer

By

Nanoliposomal irinotecan plus fluorouracil and folinic acid extends survival in patients with metastatic pancreatic cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs